Mediana has developed dozens of adaptive designs in early-stage and late-stage clinical trials, including dose-escalation designs in Phase I oncology trials and adaptive designs with sample size re-estimation, trial arm or population selection in confirmatory Phase III trials.
For more information on adaptive designs in early-stage and late-stage clinical trials, see the list of case studies based on recent consulting and software development projects.